Aspen Lung Conference: Asthma: Pathogenesis, Phenotypes, Therapies and Gaps

项目摘要/摘要 强调基础、翻译和临床方法的整合，第65届Aspen Long年会 会议将集中讨论一个中心问题：如何了解分子、基因和 哮喘发病和表型多样性的环境机制 转化为更有效的治疗方法？为了解决这个中心问题，该计划被组织成一个 一系列专题会议，由最先进的演讲者框定每个主题。专题会议将集中讨论 关于(I)哮喘的发育起源，(Ii)细胞生物学在确定哮喘内型中的作用，(Iii) 哮喘发病的微生物组和免疫机制：(Iv)细胞和分子的整合 导致哮喘临床复杂性的机制，以及(V)哮喘治疗的未来。通过 针对这些主题，我们寻求实现以下目标：1)为领先的基础、 翻译和临床研究人员就发育和细胞类型特定角色交换意见 在哮喘的表型和分子表现中对呼吸道和免疫系统的影响；2)刺激 科学领域之间的互动，以确定可能导致更有效的新的和共同的兴趣 和生产性研究；3)提高将临床前科学进步成功转化为 通过开发新的策略来更好地了解疾病的发病机制和实施，直接使患者受益 哮喘治疗的科学进展；以及4)挑战和激发学员的科学兴趣 并吸引新一代早期职业研究人员进入哮喘的广泛领域，以及潜在的 子学科包括呼吸道和肺免疫细胞生物学、遗传学和环境影响。我们有 确定了12位杰出的思想领袖，就这些主题发表了最新的演讲(35分钟)。每个人 发言之后将进行25分钟的讨论--这是本会议的一个标志。节目继续进行。 阿斯彭肺会议致力于多样性和包容性：n=8/13(62%) 演讲者/总结者是女性，我们的演讲者中至少有6人来自代表性不足的种族/民族 组。实习生和早期职业教师的参与由两个15分钟的口头摘要促进，精选 从提交的摘要中，跟随每一位最先进的演讲者(总共24人)。会有两张晚间海报 为早期职业教师和实习生提供进一步演讲机会的课程。最后的演示文稿是 由审查会议影响和共同主题的会议总结人提供。这个 会议纪要将出版广泛传播，作为一个“智囊团”，不仅 总结了该领域的当前状态，但也确定了基本、翻译和 哮喘临床研究。最后，值得注意的是，阿斯彭肺脏会议的注册是免费的，令人鼓舞 参加培训的学员和早期职业调查人员的范围很广。

PROJECT SUMMARY/ABSTRACT With an emphasis on the integration of basic, translational, and clinical approaches, the 65th annual Aspen Lung Conference will focus on a central question: how can knowledge of the molecular, genetic, and environmental mechanisms that underlie the development and phenotypic diversity of asthma be translated into more effective therapies? To address this central question, the program is organized into a series of thematic sessions, with State of the Art speakers framing each topic. The thematic sessions will focus on (i) the developmental origins of asthma, (ii) the role of cell biology in defining asthma endotypes, (iii) microbiome and immune mechanisms underlying asthma pathogenesis, (iv) integrated cell and molecular mechanisms contributing to the clinical complexity of asthma, and (v) the future of asthma therapeutics. By addressing these topics, we seek to accomplish the following: 1) provide an international forum for leading basic, translational, and clinical researchers to exchange ideas regarding the development and cell type specific roles of the airway and immune system in the phenotypic and molecular manifestations of asthma; 2) stimulate interactions between scientific fields to identify emerging and shared interests that may lead to more efficient and productive research; 3) enhance the likelihood of success in translation of preclinical scientific advances into direct patient benefit by developing novel strategies to better understand disease pathogenesis and implement scientific advances in the treatment of asthma; and 4) challenge and stimulate the scientific interests of trainees and attract a new generation of early career investigators into the broad field of asthma, as well as underlying subdisciplines including airway and lung immune cell biology, genetics, and environmental impacts. We have identified 12 outstanding thought leaders to present State of the Art lectures (35 min) on these topics. Each presentation will be followed by 25 minutes of discussion - a hallmark of the Conference. The program continues the Aspen Lung Conference’s dedication to diversity and inclusivity: n=8/13 (62%) of State of the Art speakers/Summarizer are women, and at least 6 of our speakers are from underrepresented racial/ethnic groups. Participation of trainees and early career faculty is facilitated by two 15-minute oral abstracts, selected from submitted abstracts, following each State of the Art speaker (24 total). There will be two evening poster sessions for further presentation opportunities by early career faculty and trainees. The final presentation is provided by a Conference Summarizer, who reviews the impact and common themes of the Conference. The Conference Summary will be published for widespread dissemination, to serve as a “think tank” that not only summarizes the current state of the field, but also identifies key future directions for basic, translational, and clinical asthma research. Finally, and notably, registration for the Aspen Lung Conference is free, encouraging participation from a wide spectrum of trainees and early career investigators.